Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including ...

Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and ...

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version ...

Patients would have to start with biweekly IV infusions and then would have the option ... Lilly is testing both subcutaneous injections and intravenous infusions, according to a company spokesperson.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Among those with advanced gastric cancer, oral Liporaxel showed superior overall survival outcomes versus IV Liporaxel as a ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

The FDA has approved Avtozma® (tocilizumab-anoh), a biosimilar to Actemra®, in both intravenous and subcutaneous formulations.

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...